Objective-ApoM (apolipoprotein M) binds primarily to high-density lipoprotein before to be exchanged with apoB (apolipoprotein B)-containing lipoproteins. Low-density lipoprotein (LDL) receptor-mediated clearance of apoB-containing particles could influence plasma apoM kinetics and decrease its antiatherogenic properties. In humans, we aimed to describe the interaction of apoM kinetics with other components of lipid metabolism to better define its potential benefit on atherosclerosis. Approach and Results-Fourteen male subjects received a primed infusion of 2 H 3 -leucine for 14 hours, and analyses were performed by liquid chromatography-tandem mass spectrometry from the hourly plasma samples. Fractional catabolic rates and production rates within lipoproteins were calculated using compartmental models. ApoM was found not only in high-density lipoprotein (59%) and LDL (4%) but also in a non-lipoprotein-related compartment (37%). The apoM distribution was heterogeneous within LDL and non-lipoprotein-related compartments according to plasma triglycerides (r=0.86; P<0.001). The relationships between sphingosine-1-phosphate and apoM were confirmed in all compartments (r range, 0.55-0.89; P<0.05). ApoM fractional catabolic rates and production rates were 0.16±0.07 pool/d and 0.14±0.06 mg/kg per day in high-density lipoprotein and 0.56±0.10 pool/d and 0.03±0.01 mg/kg per day in LDL, respectively. Fractional catabolic rates of LDL-apoM and LDL-apoB100 were correlated (r=0.55; P=0.042). Significant correlations were found between triglycerides and production rates of P<0.004). Conclusions-In humans, LDL kinetics play a key role in apoM turnover. Plasma triglycerides act on both apoM and sphingosine-1-phosphate distributions between lipoproteins. These results confirmed that apoM could be bound to high-density lipoprotein after secretion and then quickly exchanged with a non-lipoprotein-related compartment and to LDL to be slowly catabolized. Visual Overview-An online visual overview is available for this article. 
A poM (apolipoprotein M) is associated with high-density lipoprotein (HDL), although a small proportion binds to apoB (apolipoprotein B)-containing lipoproteins, as low-density lipoproteins (LDL). [1] [2] [3] ApoM was shown to be involved in lipid metabolism 3 and could also be a mediator of several atheroprotective effects attributed to HDL. [4] [5] [6] [7] ApoM is mainly produced by the liver and the kidney, 8, 9 and its plasma concentration is correlated with total cholesterol, HDL cholesterol (HDL-C), and LDL cholesterol. 10 ApoM is a member of lipocalin family and owns a hydrophobic pocket enabling the binding of small functional lipids, such as sphingosine-1-phosphate (S1P).
3 S1P is known to have protective actions on the cardiovascular system, and apoM is its main plasma carrier with the plasma albumin. 11 However, the atheroprotective effects attributed to apoM in association with S1P remains an open question. 12 Kinetic studies with stable isotope tracers have provided important knowledge in lipoprotein metabolism, 13 recently improved by new advances in mass spectrometry. [14] [15] [16] These new approaches, based on an enzymatic proteolysis and targeted analysis of specific peptides by liquid chromatographytandem mass spectrometry, allowed the measurements of apolipoproteins not previously studied. 14 Reports have already shown that plasma apoM concentrations were negatively associated with catabolic rates of HDL 17 and LDL, 18 but to our knowledge, no study focused on the whole-body apoM kinetics except 1 study from Singh et al 16 who analyzed the kinetics of several apolipoproteins but only in different HDL subfractions. Here, we aimed to perform a specific kinetic study of the apoM to give further insights on its metabolism and the relationship with a wide range of lipoprotein components to identify the potential links with cardiovascular prevention.
Materials and Methods
Fourteen male subjects carrying a broad range of lipid parameters (age: 18-63 years; body mass index: 18-34 kg/m 2 ; 6 healthy subjects; 8 subjects with a mild hypertriglyceridemia) were enrolled. Plasma lipids and lipoproteins and lipoprotein kinetics were assessed as described in detail in the section on Materials and Methods available in the online-only Data Supplement.
Results

Plasma Apolipoprotein M and S1P
The patients displayed a broad range of lipid and apolipoprotein concentrations as shown in Table 1 (mean±SD concentrations of LDL cholesterol: 113.0±42.2 mg/dL; HDL-C: 46.3±12.9 mg/dL; plasma triglyceride: 158.7±91.2 mg/dL). Total plasma apoM (2.7±0.8 mg/dL or 1.3±0.4 µmol/L) and S1P (269.0±91.9 nmol/L) were in the usual reported ranges. As expected, S1P and apoM were mainly recovered in HDL fractions (36% and 59%, respectively) and, in a lower extent, in LDL fractions (8% and 4%, respectively). We also observed that 56% of S1P and 37% of apoM seemed to be non-lipoprotein-related (NLR). This was not because of technical processes because we obtained similar recovery with sequential ultracentrifugation and fast protein liquid chromatography methods ( Figure I in the online-only Data Supplement).
Assuming a mean of 3 apoA-I units per HDL particles, we estimated that 5.1±0.4% (range, 2.7%-7.3%) of HDL particles could carry 1 apoM. These ratios were relatively homogeneous (coefficient of variation [CV]=28.2%), although HDL particles are able to carry 2 to 4 apoA-I units. In LDL, 4.8±0.8% (range, 0.9%-9.1%) of particles could carry 1 apoM. Considering 1 apoB100 per LDL particle, these ratios were heterogeneous (CV=66.3%) and significantly associated with plasma triglyceride (r=0.86; P<0.001), total cholesterol (r=0.55; P=0.05), and non-HDL-C (r=0.70; P=0.007). This strong variability was also observed for both NLR-S1P and NLR-apoM concentrations, which were again significantly correlated with plasma triglyceride (r=0.85; P<0.001 and r=0.71; P=0.006, respectively). The S1P/apoM molar ratios calculated in each subfraction were 0.22±0.08, 0.77±1.06, 0.14±0.04, and 0.43±0.10, for total plasma, NLR, HDL, and LDL, respectively. These ratios were again heterogeneous in the NLR compartment (CV=137%) compared with the others (total plasma, CV=37.6%; HDL, CV=31.6%; LDL, CV=22.5%).
As expected (Figure 1 ), S1P and apoM concentrations were significantly correlated in all compartments, with the strongest association in the LDL fraction. Additional correlations with S1P and apoM are shown in the Table II in the online-only Data Supplement. We observed strong associations between total plasma and LDL apoM concentrations (r=0.71; P=0.006) and between total plasma and LDL-S1P concentrations (r=0.63; P=0.019). Other associations obtained between lipids and apolipoproteins were investigated (Tables III and IV in the online-only Data Supplement; Figure  II in the online-only Data Supplement). We found significant associations in whole plasma between apoM and apoA-II, triglyceride or non-HDL-C. In both LDL and NLR fractions, apoM concentrations were positively associated with plasma triglyceride, total cholesterol, and their related parameters (plasma apoB100, PCSK9 [proprotein convertase subtilisin/ kexin type 9], apoC-II, apoC-III, and apoE). Finally, in HDL, apoM concentrations were positively associated with HDLapoA-I and HDL-apoA-II concentrations but not with apoE or plasma triglyceride. Similar results were observed for S1P but not with the S1P/apoM molar ratios and the other lipid data.
Apolipoprotein Kinetics
Enrichment curves are shown in Figure 2A . LDL-apoM enrichments presented a slight delay in comparison to those of HDL-apoM or NLR-apoM, suggesting that apoM could be released into the plasma via the HDL or NLR fractions and then exchanged to the LDL. In addition, apoM did not reach the asymptotic enrichment plateau in both compartments, suggesting of slow turnover rate. Kinetic parameters obtained for apoM, apoA-I, apoA-II, and apoB100 are shown in Table 2 . ApoA-I, apoA-II, and apoB100 kinetic data were in the usual reported ranges even we noticed a higher catabolic rate for HDL-apoA-II than those of HDL-apoA-I, likely because of 2 outlier patients (0.479 and 0.432 pool/d). ApoM enrichments were analyzed by a multicompartmental model involving a first entrance into the HDL ( Figure 2B ) and exchanges to NLR and LDL (back-calculated CV ranging 5.7%-16.1% for all variables). We also investigated 2 additional models for apoM kinetics (Table V in the online-only Data Supplement; Figure III in the online-only Data Supplement). A multicompartmental model involving the NLR compartment as a first entrance (model 2) was not retained because it did not allow to get an acceptable mass balance. In addition, the calculated kinetic parameters were poorly correlated with those obtained by the 3 independent monocompartment models (model 3). Model 3 was not retained because it was less informative than the selected model 1 because apoM exchanges between particles were not calculated. However, we observed that the kinetic parameters obtained with the selected model ( Figure 2B ) were slightly different than those obtained with a monocompartmental modeling, especially for the LDL and the HDL.
Correlations between kinetic data of apoM and other apolipoproteins are shown in Table 3 . A significant correlation between LDL-apoB100 and LDL-apoM fractional catabolic rate was found (r=0.55; P=0.042). LDL-apoM and HDLapoM fractional catabolic rate were inversely correlated, but no significant correlation was found between kinetics of HDLapoM and HDL-apoA-I or HDL-A-II. Kinetics of NLR-apoM showed similar associations with other apolipoprotein kinetics than those observed for LDL-apoM. The rates of apoM exchanges between lipoproteins were strongly associated with LDL-apoM kinetics (Table 3) . HDL-apoM kinetics were positively correlated with HDL-C and plasma apoA-I concentrations. LDL-apoM production rate (PR) was positively correlated with plasma S1P, triglyceride, apoB100, apoC-II, apoC-III, apoE, and PCSK9 (Table 4 ). The exchanges of apoM between HDL and NLR were positively associated with plasma triglyceride (r=0.57; P=0.037) and plasma S1P (r=0.62; P=0.021), whereas apoM transfer from HDL to LDL was positively correlated with apoA-II, apoC-II, apoC-III, PCSK9, LDL-S1P, and NLR-apoM (Table 4) .
Nonstandard Abbreviations and Acronyms
ApoM and S1P concentrations were compared with apolipoprotein kinetics. In LDL and NLR compartments, both S1P and apoM concentrations were positively associated with LDL-apoM kinetics, and NLR-apoM concentrations were also inversely correlated with HDL-apoM kinetic parameters (Table VI in the online-only Data Supplement). No significant relationship was found for HDL-S1P or HDL-apoM concentrations and lipoprotein kinetics except for HDL-apoA-I PR that correlated with HDL-apoM concentrations (r=0.622; P=0.020). The rates of apoM transfers between compartments and NLR-apoM kinetics were positively correlated with plasma and NLR-S1P concentrations. Mean (range) expressed in milligrams per deciliter otherwise specified. Apo indicates apolipoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9; S1P, sphingosine-1-phosphate; and VLDL, very low-density lipoprotein. 
Discussion
Chemistry of apoM and its anchorage in HDL via a retained signal peptide is well characterized, but little is known on its metabolism. 19 Most of the information came from animal models or extreme phenotype patients. 3, 5, 17, 18, 20 We have studied apoM kinetics in humans, and we observed a relationship between LDL catabolic pathways. We do confirm a high affinity of apoM and S1P within HDL particles, and we also underlined that plasma triglyceride is involved in apoM distribution and kinetics in the lipoprotein fractions.
We observed that apoM is primarily associated to HDL, even if a small proportion was found in apoB-containing lipoproteins, mainly LDL as previously reported. 1, 2, 20 We found plasma apoM concentrations correlated with non-HDL-C but surprisingly not with HDL-C, LDL cholesterol, and total cholesterol as reported before. 10, 17 This might be related to the low number of included subjects, as the previous reports analyzed more patients (from 60 to 566) and obtained significant but slight correlations (r coefficient from 0.4 to 0.5). We also confirmed the strong correlation between apoM and S1P in total plasma, HDL, and LDL, 3, 11 but also in a NLR compartment. This NLR fraction was not extensively described because most of the studies focused on apoM distribution within plasma lipoproteins using gel electrophoresis or related methods.
1,2,20 Using 2 different approaches, we have identified an apoM fraction not carried by lipoproteins, which also binds S1P in plasma besides the albumin. 11 Both apoM and S1P varied heterogeneously in this compartment between the subjects in association with plasma triglyceride. In addition, it was established that ≈2% of LDL and 5% of HDL could carry apoM molecules. 3 This was confirmed for HDL, while we noticed a strong heterogeneity in LDL in association with plasma triglyceride. This effect of plasma triglyceride on apoM concentrations was previously described 3, 18 and was suggested as a possible explanation to the increased levels of S1P reported in obese patients. 21 A previous study also concluded that the ability of apoM to exchange between plasma lipoproteins could be related to a quick replenishment of the pool of apoM in LDL from HDL and subsequently to the catabolism of an apoM via the clearance of apoB-containing particles. 18 In this report, the authors also showed, as we observed, that elevated plasma triglyceride increased apoM concentrations in LDL. On the same lines, another study demonstrated that apoM was bound preferentially in plasma LDL in patients with low HDL-C, usually observed with increased triglyceride in the so-called atherogenic dyslipidemia. 22 Our data reinforce the role of the atherogenic lipid profile because triglyceride influenced apoM contents not only in LDL but also in NLR fractions as well as in S1P plasma concentrations. We can, therefore, speculate that plasma triglyceride plays a Spearman correlation test (r coefficients; P values). Apo indicates apolipoprotein; FCR, fractional catabolic rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n/a, not applicable; NLR, non-lipoprotein-related; NS, not significant (P>0.05); PR, production rate; and VLDL, very-low-density lipoprotein. Spearman correlation test (r coefficients; P values). Apo indicates apolipoprotein; FCR, fractional catabolic rate; HDL, high-density lipoprotein; HDL-C, HDL cholesterol; LDL, low-density lipoprotein; LDL-C, LDL cholesterol; NLR, non-lipoprotein-related; NS, not significant (P>0.05); PCSK9, proprotein convertase subtilisin/kexin type 9; PR, production rate; and S1P, sphingosine-1-phosphate.
critical role for the transfer of apoM toward LDL particles. Unfortunately, from our kinetic data, we could not identify any mechanism because we did not observe any correlation between very-low-density lipoprotein-apoB100 kinetics and apoM concentrations or kinetics. It is likely that triglyceride could modulate the strength of the apoM linkage by changing the composition of the HDL and LDL. A recent study has already pointed out the 10-fold stronger affinity of S1P/apoM within LDL compared with HDL. 23 High triglyceride could amplify this difference and facilitate the exchange of apoM from HDL to LDL, but this needs to be demonstrated. In a previous report in mice, it was suggested that high triglyceride and apoM distribution could be related to the very-lowdensity lipoprotein clearance rate and the apoE. 20 Our data do not support these mice results in humans.
After liver synthesis, apoM is supposed to be secreted into the plasma where it binds to HDL 3 before to be exchanged with apoB-containing lipoproteins. 18, 20 Our kinetic data support this hypothesis because we observed a slight delay between both HDL-and LDL-apoM kinetic curves. From this background and a cluster analysis, we developed 3 plausible multicompartmental models to analyze the apoM kinetics. Besides the HDL and LDL, the addition of the NLR compartment was required to get better fits and a mass balance between the pools. We have selected 1 multicompartmental model able to describe apoM kinetics and exchanges between lipoproteins unlike the robust 3 monocompartment models, although comparable results were obtained for most of the data. Some limitations of the selected model must be underlined because LDL-apoM or HDL-apoM fractional catabolic rate were significantly different from those observed for LDL-apoB100 (higher) or HDLapoA-I (lower), despite similar enrichment curves. We cannot exclude that this model slightly overestimated (LDL) or underestimated (HDL) the catabolic rates of apoM. Nonetheless, kinetic data were in the same range and were correlated with those obtained from the 3 monoexponential modeling.
We do confirm the fast exchanges between the pools. 20 Because of the number of patients, we were not able to confirm the inverse associations found previously between plasma apoM and catabolic rates of HDL-apoA-I in 60 patients with hypertriglyceridemia. 17 As mentioned earlier, triglyceride plays a central role not only on plasma apoM but also on HDL-apoA-I catabolism, 24 and it is unclear whether this correlation remains when adjusted on triglyceride. The lack of association we have observed could also suggest that apoM and apoA-I behaved differently through the HDL degradation and clearance. It is still not known whether they remained together on the particles with the action of the hepatic lipase and the cholesterol exchange through the SR-B1 (scavenger receptor class B type I).
We confirmed that plasma apoM could be catabolized through LDL particles as previously suggested in mice 20 and reported in humans, 18 although LDL did not constitute its main carrier. 1, 3, 18 As HDL-apoM pool size is much bigger than those of LDL-apoM, we hypothesized that the HDL, as well as the NLR compartments, act as reservoirs for LDL-apoM, assuming a fast exchange between them until transfer and clearance of apoM through LDL. We were not able to confirm the impact of LDL catabolic rate on the total plasma apoM concentration, 18 again probably because of the number of patients, but
we found a significant and positive association for catabolic rates of LDL-apoM with those of LDL-apoB100. Besides, PR of LDL-apoM and LDL-apoM concentrations were associated with PCSK9 plasma levels, a natural inhibitor of LDL receptor. 25 All together, these data support the key role of the LDL receptor in the disappearance of plasma apoM.
In sharp difference with the HDL, it is likely that the strong affinity of apoM with the LDL explained their joined clearance. Noteworthy, our kinetic data are not comparable with those recently reported on HDL-apoM on 3 subjects. 16 We found lower catabolic or PRs and lower pool sizes. Besides the model used, we have only enrolled men, whereas 2 of the 3 subjects analyzed in the other study were women. It was shown that estrogens increased the synthesis of apoM, 26 and sex differences are likely 20 but deserve additional studies. Triglycerides are other candidates to explain such a difference because they seemed to increase the rate of LDL-apoM production by improving the exchanges of apoM between compartments.
Finally, S1P is a signaling sphingolipid regulating pro-and antiatherogenic processes, and increased plasma S1P concentrations could protect against atherosclerosis and related diseases. 27 However, it remains difficult to clearly settle on the role of S1P within lipoproteins because distinct pools of plasma S1P exist (HDL-S1P and albumin-S1P) with different physiological roles. 11 We confirmed that circulating S1P increased in association with plasma triglyceride as previously reported 21 and showed that elevated plasma S1P is related to apoM PR in the LDL compartment, whereas no association was found with HDL-apoM kinetics. We have also identified a novel plasma pool of S1P in the plasma, which was not related to lipoproteins or plasma albumin and linked to unbound apoM. Again, this plasma pool of S1P seemed to be strongly associated with plasma triglyceride. The contribution of S1P to apoM fluxes between lipoprotein particles or to the apoM clearance via the LDL pathway is difficult to dissect out from our data. Kinetic studies of apoM and S1P plasma distribution in patients with extreme phenotypes (from identified mutations, eg, familial hypercholesterolemia) or under specific treatments acting with different mechanisms (eg, statins, fibrates, and nicotinic acid) could be useful to gain further knowledge on this aspect.
In conclusion, we were able to investigate apoM kinetics in lipoprotein fractions using novel mass spectrometry-based methods. We also showed that plasma triglyceride could play a central role in both apoM and S1P distribution between lipoprotein classes, and our results underlined the key role of LDL kinetics in apoM turnover. Hence, our results pave the way for further investigations, which are required to clearly settle the role of apoM in atherosclerosis prevention.
